In all of its locations HOYNG ROKH MONEGIER services the needs of clients in the field of intellectual property law, including patents and trade secrets, trademarks, copyrights and design rights, as well as in related fields, such as pharmaceutical regulatory law, unfair competition, media and advertising law and all IP related contracts.
Our services
Unified Patent Court
Arbitration & Mediation
CJEU & supreme court litigation
Copyright
Life sciences regulatory
Patents
Trademark & Design
Unfair competition & Trade secrets
IP Licensing & Transfer
Aerospace, automotive & marine
Biotechnology & Biologics
Chemicals
Electronics, computers, software & semiconductors
Pharmaceuticals
Industrial equipment & Manufacturing
Telecommunications & Networks
Retail & Consumer goods
Fashion & Luxury goods
Media
Medical devices
Awards & Rankings
Case Studies
Website blocking orders in Europe
In 2012, HOYNG ROKH MONEGIER obtained the first website blocking order in the Netherlands on behalf of a number of movie studios (represented by anti-piracy organisation BREIN). On appeal, the order was suspended due to an incorrect application of the law by the court of appeal. The appellate court’s decision was successfully appealed to – and overturned by – the Dutch Supreme Court and subsequently the Court of Justice of the European Union. In January 2018, HOYNG ROKH MONEGIER obtained yet another important victory for the same movie studios, this time coordinated by the Motion Picture Association (MPA ): the first website blocking order in Spain for the film industry. The Spanish decision was not appealed and has thus become final.
ASML and Carl Zeiss SMT v. Nikon – immersion lithography
ASML Netherlands BV is the world’s largest manufacturer of lithography machines used in the production of computer chips. ASML’s high-tech lithography machines produce computer chips with nanometer precision (a nanometer is approximately 100,000 times thinner than a strand of human hair).
Lundbeck v. Tiefenbacher et al. – escitalopram
In 1972, the Danish pharmaceutical company H. Lundbeck A/S synthesised an organic compound known as citalopram. Citalopram was found to have a significant antidepressant effect as a selective serotonin reuptake inhibitor (SSRI). The new drug was launched by Lundbeck in 1989 under the brand name Cipramil® and was very successful.